Wegovy Pills vs Mounjaro: Which Is Right for You?

Last updated: 17 June 2026

How they work: semaglutide vs tirzepatide

How Wegovy pills compare to Mounjaro starts with the science. They work differently.

The Wegovy pill contains semaglutide, a type of medicine called a GLP-1 receptor agonist. Semaglutide copies a gut hormone your body makes naturally. That hormone, GLP-1, signals fullness to your brain and slows digestion.

Tirzepatide, the active ingredient in Mounjaro, is made by Eli Lilly. Unlike semaglutide, it targets two gut hormones: GLP-1 and GIP. GIP plays a role in appetite and blood sugar. Targeting both hormones is thought to be why Mounjaro helps people lose weight faster in trials.

Efficacy: what the evidence shows

Until SURMOUNT-5, nobody had tested Mounjaro vs Wegovy head-to-head. This trial ran for 72 weeks. 751 adults with obesity were given one of the two drugs by injection, at the highest dose they could tolerate. The Mounjaro group lost an average 20.2% of their body weight. The Wegovy group lost 13.7%.

So is Mounjaro more effective than Wegovy pills? The injectable data says yes. But SURMOUNT-5 compared two injectable treatments. Everyone in the Wegovy group received the injection at doses up to 2.4mg. Nobody in the trial took the pill. To this day, no trial has tested the Wegovy pill against Mounjaro. Any oral Wegovy vs Mounjaro comparison is based on separate studies.

Wegovy pills weight loss results show an average of 13.6% body weight lost in just over a year. This data comes from the OASIS 4 trial.

If your BMI is above 45, Mounjaro’s extra weight loss could take you below health risk levels that the Wegovy pill may not reach. 

If your BMI is 30–35, the weight loss from oral Wegovy may already be enough to reach a healthy range. At that starting point, the extra weight loss changes the number on the scale, not your actual health risk.

Administration: daily pill vs weekly injection

What does each treatment actually ask of you?

The rules are strict. You take the Wegovy pill first thing in the morning, on an empty stomach, with no more than 4 ounces/120ml of plain water. Nothing else for 30 minutes. No food, no coffee, no other tablets. These may dilute the medication, affecting the absorption and effectiveness.

Why? The pill contains an absorption enhancer called SNAC. It only works properly on a completely empty stomach. Break these rules, and the drug may not get absorbed.

Mounjaro is different. One injection a week, at any time of day — no food rules.

None of that matters if you have a needle phobia. For some people, the injection itself is the problem. The Wegovy pill takes that problem away.

Side effects

Both treatments can upset the gut. Nausea, vomiting, diarrhoea, and constipation are all common side effects. That part is the same.

In OASIS 4, 74% of participants on oral semaglutide reported at least one gut-related side effect. In SURMOUNT-5, more people stopped treatment because of side effects on injectable semaglutide than on tirzepatide.

When comparing Wegovy pill vs Mounjaro side effects, symptoms are similar, but timing often differs. You take the Wegovy pill after fasting overnight, so nausea hits before you’ve eaten. The side effects of Wegovy pills are not severe for most people, but nausea on an empty stomach every morning becomes the reason some quit.

With Mounjaro, you can eat first. That makes a difference. Some people get itching or redness at the injection site, but it tends to be mild.

UK access

The MHRA approved the Wegovy pill in June 2026, making it the first oral GLP-1 licensed for weight management in the UK. Mounjaro and injectable Wegovy are also available through the NHS and private prescription.

You typically need a BMI of 30 or above, or 27 or above with a weight-related health condition like high blood pressure, type 2 diabetes or high cholesterol. Lower thresholds apply for people from South Asian, Chinese, Black African or Black Caribbean backgrounds. Your prescriber will review your medical history before you start your weight loss journey.

NHS eligibility criteria are currently stricter than private prescribing criteria. Check with your prescriber or pharmacy for the most up-to-date access and stock information.

For anyone weighing up the Wegovy pill vs Mounjaro in the UK, both are licensed treatments. Your prescriber can confirm which is available and suitable for you.

Which is right for you?

The Wegovy pills vs Mounjaro decision comes down to trade-offs.

Mounjaro suits you if maximum weight loss is your priority. If your starting BMI is high, the extra weight loss will help you to reach health benefits that the pill may not. Its weekly routine suits busy or unpredictable mornings. 

Avoid it if needle phobia is a genuine barrier. No amount of trial data changes anything if you won’t inject. 

The Wegovy pill suits you if the thought of injecting has stopped you from starting treatment. At a BMI of 30–35, the pill’s weight loss may be enough to reach a healthy range on its own. 

Avoid it if your mornings are unpredictable or if you already get morning nausea. The 30-minute fast is not optional. If you can’t do it reliably, the pill won’t work.

The choice between Wegovy pills vs the injection comes down to which format fits your life. Your weight loss journey depends as much on the routine as on the drug. Either way, diet and exercise alongside the medication will get you further than the drug alone.

When should I see a doctor?

Mild nausea or diarrhoea? Questions about your dose? Contact us. We can look at your medical history and treatment plan, adjust your dose or talk through whether to switch from Mounjaro to Wegovy.

If something feels more serious, or you notice symptoms you wouldn’t expect from your treatment, see your GP or call NHS 111.

Call 999 or go to A&E if you experience:

• Severe upper stomach pain that spreads to your back, with nausea or vomiting. This can be a sign of pancreatitis (inflammation of the pancreas).
• Swelling of the face, lips, tongue or throat. Difficulty breathing. Severe rash. These could mean an allergic reaction.
• Sudden changes to your vision. In 2026, the MHRA flagged a rare eye condition called NAION in people taking semaglutide.
• Vomiting or diarrhoea that won’t settle. This can lead to dehydration and kidney problems.

Frequently asked questions

Wegovy pill or Mounjaro: which is better? 

In short, neither. They do different things. Mounjaro produces more weight loss but needs a weekly injection. The Wegovy pill avoids the needle but demands a strict daily routine.

Which weight loss injection is best in the UK? 

Mounjaro produced the highest average weight loss in head-to-head injectable trials. If the fasting-free weekly routine suits your life, it is the stronger option on current evidence.

What is the difference between Mounjaro vs oral Wegovy? 

One is a weekly injection with no food restrictions. The other is a daily pill with a strict 30-minute fast. Mounjaro targets two gut hormones and produces more weight loss. Oral Wegovy targets one, but removes the needle.

Key takeaways

• The first Wegovy vs Mounjaro head-to-head trial gave Mounjaro the edge: 20.2% average weight loss vs 13.7% for injectable Wegovy. No trial has compared the pill with Mounjaro directly.
• The Wegovy pill (13.6% average weight loss) is the only oral option in this class. It suits people who won’t or can’t inject.
• The pill may be enough for people with lower starting BMIs. At a BMI above 45, Mounjaro’s extra weight loss is more likely to make a difference to your actual health risk.
• The pill requires strict daily fasting. Mounjaro’s weekly injection does not.

References

Mounjaro (tirzepatide) Summary of Product Characteristics, Eli Lilly, Medicines.org.uk [Accessed 7 April 2026].

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine [Accessed 7 April 2026].

Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity. New England Journal of Medicine [Accessed 7 April 2026].

MHRA Authorises Mounjaro (Tirzepatide) for Weight Management and Weight Loss. GOV.UK, 8 November 2023 [Accessed 7 April 2026].

Tirzepatide for Managing Overweight and Obesity (TA1026). National Institute for Health and Care Excellence [Accessed 7 April 2026].

Drug Safety Update, January/February 2026: GLP-1 Receptor Agonists. GOV.UK [Accessed 7 April 2026].

MHRA Updates Guidance for Semaglutide Prescribers and Patients (NAION). GOV.UK, 5 February 2026 [Accessed 7 April 2026].

Switching Between Weight-Loss Medications, The Pharmaceutical Journal, December 2025 [Accessed 7 April 2026].

First GLP-1 tablet for weight loss approved in the UK, Medicines and Healthcare products Regulatory Agency, 2026 [Accessed 16 June 2026]. 

Wegovy 25 mg tablets – Summary of Product Characteristics, electronic medicines compendium (eMC), 2026 [Accessed 17 June 2026]. 

Authorship